Brontictuzumab (INN; development code OMP-52M51) is a humanized monoclonal antibody designed for the treatment of cancer.[1][2]
This drug was developed by OncoMed Pharmaceuticals.
Ilm, huumor ja uudiseid
Brontictuzumab (INN; development code OMP-52M51) is a humanized monoclonal antibody designed for the treatment of cancer.[1][2]
This drug was developed by OncoMed Pharmaceuticals.